Cart
sales@molnova.com
Methyltetrazine-Amine
CAS No. 1345955-28-3
Methyltetrazine-Amine( —— )
Catalog No. M33701 CAS No. 1345955-28-3
Methyltetrazine-Amine is a methyl-substituted tetrazine amine used in the synthesis of PROTAC molecules.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 29 | In Stock |
|
| 10MG | 40 | In Stock |
|
| 25MG | 77 | In Stock |
|
| 50MG | 120 | In Stock |
|
| 100MG | 194 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMethyltetrazine-Amine
-
NoteResearch use only, not for human use.
-
Brief DescriptionMethyltetrazine-Amine is a methyl-substituted tetrazine amine used in the synthesis of PROTAC molecules.
-
DescriptionMethyltetrazine-Amine, a tetrazine compound, is used for the site-specific dual functionalization of the resulting bioconjugates.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPROTACs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1345955-28-3
-
Formula Weight201.23
-
Molecular FormulaC10H11N5
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20.83 mg/mL (103.51 mM; ultrasonic and warming and adjust pH to 2 with HCl and heat to 60°C; )
-
SMILESN=1N=C(N=NC1C=2C=CC(=CC2)CN)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Antoine Maruani, et al. A Plug-and-Play Approach for the De Novo Generation of Dually Functionalized Bispecifics. Bioconjug Chem. 2020 Mar 18;31(3):520-529.?
molnova catalog
related products
-
Cyclo(Ile-Val)
Cyclo(Ile-Val) shows moderate antifungal and weak antitumor activities in vitro.
-
Tripchlorolide
Tripchloride has antitumor ,anti-inflammatory,immunosuppressive and powerful neuroprotective properties.
-
Memantine
Memantine, an amantadine derivative with some dopaminergic effects, has been proposed as an antiparkinson agent and has may be used to treat moderate to severe Alzheimer's disease. It acts on the glutamatergic system by blocking NMDA receptors.
